ライフサイエンスコーパス: patient

1 lance group was myocardial infarction (three patients).

2 ing the entire follow-up experience for each patient.

3 me to nearly 20% of the world's "missing" TB patients.

4 ing 168 longitudinal samples belonging to 66 patients.

5 iate between that of controllers and treated patients.

6 clinical course of follicular lymphoma (FL) patients.

7 ckable arrest rhythms were noted in 23.3% of patients.

8 Association class IV (NYHA IV) heart failure patients.

9 g novel therapies should be focused on these patients.

10 as a candidate therapeutic target in glioma patients.

11 the setting of high risk, heavily pretreated patients.

12 cific Islander/American Indian/Alaska Native patients.

13 their divergence in longitudinally monitored patients.

14 healthy controls and different from non-TMSR patients.

15 audio-recorded discussions between PCPs and patients.

16 rties in both healthy individuals and cancer patients.

17 ith metastatic status in human breast cancer patients.

18 dmission for heart failure was reached in 88 patients.

19 16, and the second validation cohort had 265 patients.

20 Fifty-one patients (11.9%) discontinued from the study during the

21 Causal copy-number variants were found in 12 patients (11.9%) with multiple diagnoses.

22 In the randomly assigned patients, 21 patients in the VRd group and 31 in the Rd

23 Overall, SVR12 was achieved by 98% of patients (51/52; 95% confidence interval, 90%-100%).

24 Of 863 patients, 551 (63.9%) were male and median age was 58 ye

25 Sixteen patients (64%) presented with photopsias, 56% (14/25) wi

26 ied as indeterminate, while the remaining 17 patients (8%) served as controls, with infections by eit

27 One hundred eighty-seven patients (92%) were classified as indeterminate, while t

28 sone should be offered after discussion with patients about potential harms, benefits, costs, and pat

29 new-onset depression and anxiety among adult patients admitted to an ICU.

30 Clinicians may help protect patients after discharge by serving as a liaison between

31 Study sample size, patient age, follow-up time, timing of MRD assessment (p

32 IRs among patients aged 0-4 years were more than double overall IR

33 METHODS AND Twenty-five patients aged median 12.0 years after repair of tetralog

34 Eight studies comprising 1511 patients (all children) met eligibility criteria.

35 We identified 1044 patients, among whom 460 (44.1%) received upfront surger

36 Patient and investigator perspectives were elicited by s

37 A total of 50 subjects (30 patients and 20 surrogates) were enrolled.

38 MATERIAL/Forty-five stroke patients and 45 age- and sex-matched controls were recru

39 light increase in number was observed in ASD patients and family members compared to controls, there

40 Patients and investigators were masked to treatment assi

41 ifferences in clinical outcomes between MGUS patients and KT controls.

42 Patients and Methods This phase I study tested the combi

43 (GEP) from a cohort of multiple myeloma (MM) patients and normal individuals using global reasoning o

44 iatric oncology patients, is the notion that patients and their families may not need or want palliat

45 010, and Dec 7, 2015, the trial enrolled 399 patients and was terminated after a planned interim futi

46 n group (diarrhoea and urinary sepsis in one patient, and acute renal failure and respiratory failure

47 and imaging biomarkers to identify high-risk patients, and clinical trials evaluating novel therapies

48 ion, notification, and evaluation of exposed patients, and management of HCDs with regard to placemen

49 patient presents a unique challenge as many patients are at high or prohibitive surgical risk and, t

50 Because more patients are being treated with alternative programs, co

51 Septic patients are especially prone to IIT-induced hypoglycemi

52 Focused analyses with aminoglycoside-treated patients are needed next to evaluate a possible interfer

53 ients with severe liver trauma (SLT), in ALF patients as a bridge to transplantation (BTT), and as de

54 rther course of rituximab was required for 4 patients as a result of FSGS relapse, with good results.

55 disparity in the referral of black and white patients as a secondary outcome.

56 an-Meier estimates of reengagement among all patients as well as the subset of LTFU patients who were

57 Secondary objectives included patients' assessment of their gastrointestinal symptoms

58 ll numbers (ie, the level of bacteremia), in patients at the time of clinical presentation on IL-10 p

59 formed over a 5-year period using records of patients' biodata, MRI date, indication, findings and sc

60 creased between 2012 and 2014 (2,201 v 2,558 patient cases; 2,278 v 2,659 tumors), HER2 positivity re

61 Guidelines for support of the family in the patient-centered ICU.

62 or the development of ARDS and for important patient-centered outcomes like mortality.

63 We conclude that a patient-centered, individualized, and parsimonious appro

64 B+) microvesicles were also increased in AMR patients compared with no AMR and healthy subjects.

65 Patients consumed, on average, 17.5% of energy of total

66 he annualised pulmonary exacerbation rate in patients continuing treatment through extension week 96

67 examine the risk and determinants of HCC in patients cured with DAA.

68 Individual patient data on SAEs, assigned drug and dosing regimen,

69 verage of 13.0 cases to 9.7 cases per 10,000 patient-days (P = 0.008).

70 upport the hypothesis, in a subpopulation of patients, DCs recruited at the diseased tissue produce h

71 Six patient deaths occurred, all deemed related to underlyin

72 One patient developed decreased visual acuity secondary to r

73 l multicenter study of all consecutive adult patients diagnosed with anti-NMDAR encephalitis at the F

74 dverse events associated with death, and one patient died from treatment-related adverse events (myos

75 nterquartile range, 3.5-6.0 years), 38 (15%) patients died and 106 (41%) either died or developed ind

76 17 (5%) of 370 patients died from non-treatment-related adverse events

77 Overall, 18 (22%) of 83 patients discontinued therapy due to treatment-related t

78 Patient doses in this study was higher compared to previ

79 in in control subjects and in critically ill patients, during feeding and fasting, and to search for

80 as a tool to characterize the phenotypes of patients exhibiting various syndromes.

81 Given many BRAF-mutated melanoma patients experience disease progression with targeted BR

82 Work-related asthma patients exposed to protein allergens and isocyanates el

83 mpared to previous research, suggesting that patients exposed to unnecessary radiation.

84 AR1*557Gluext*46 mutant protein expressed in patient fibroblasts was comparable to levels of WT IFNAR

85 ther explore the genetics in a larger set of patients following-up on the most promising genomic regi

86 ved percutaneously, rendering 34 (54%) of 63 patients fragment free.

87 NT Anxiety and posttraumatic stress disorder patients generalize fear to nonfearful fear stimuli, mak

88 iven an electronic prescription (15.2%) than patients given a paper prescription (31.5%).

89 herence was 16 percentage points lower among patients given an electronic prescription (15.2%) than p

90 eased SVR rates for certain DAA regimens and patient groups.

91 No patient had a manic switch or was hospitalized for a swi

92 Younger patients had a higher likelihood of complete clinical su

93 Eleven of the 434 patients had another infection within 6 months, but only

94 Fifty-five percent of patients had grade 3 or 4 neurologic toxicities that com

95 previous lines of therapy was two (2-5), 38 patients had high-risk cytogenetics, 17 were unresponsiv

96 husetts Eye and Ear Infirmary, 48 eyes of 44 patients had keratoprosthesis type II implanted by 2 sur

97 More than one third of U.S. HIV patients had missed opportunities to initiate hepatitis

98 d culture to promote safe work practices for patient handling injury prevention.

99 communication support program did not impact patients' health-related quality-of-life or the likeliho

100 al prognostic use of indexing aortic root to patient height.

101 cagrelor appears to provide higher value for patients in several recognized high-risk subgroups.

102 remained effective after inclusion of older patients in the analysis.

103 -node metastases, identified in 11.5% of the patients in the dissection group, were a strong, indepen

104 In the randomly assigned patients, 21 patients in the VRd group and 31 in the Rd group were de

105 From 2006 to 2012 the use of PC in ESLD patients increased substantially; socioeconomic, geograp

106 Delirium in critically ill patients is associated with poor clinical outcomes.

107 onstrate that barrier leakiness in asthmatic patients is induced by TH2 cells, IL-4, and IL-13 and HD

108 d barrier, especially for pediatric oncology patients, is the notion that patients and their families

109 s suggest that overgeneralization in anxiety patients may be mediated by an inability to recruit the

110 ons in the interstitial tissue, confirmed in patients, may have important implications for biotherapi

111 Among 336 randomized patients (mean age, 68 years; 16% women), 333 completed

112 In these patients, median age was 58 years (IQR 51-62), median nu

113 previous survey suggesting that one-third of patients might be willing to donate at imminent death, w

114 We observed that 104 461 (19.0%) patients missed more than two appointments in the 3 year

115 Patients missing >/=8 consecutive days of ibrutinib had

116 ible method for automating evaluation of ICU patient mobility.

117 olone (moxifloxacin or levofloxacin) use and patient mortality, adjusting for risk factors typically

118 ts with BOS (n = 10), stable lung transplant patients (n = 18), and healthy aged-matched controls (n

119 Among the patients (n = 19) whose HBsAg levels ever dropped below

120 Patients (n = 221) had peanut sensitivity and positive d

121 r Data Base, which includes more than 70% of patients newly diagnosed as having cancer in the United

122 Patients newly diagnosed as having cT1-2 N1-2b pathologi

123 MRSA hand carriage rates in patients, nurses, and dentists were 9.8%, 6.6%, and 5%.

124 Across seven patients, odor stimulation enhanced theta power in human

125 Purposeful sampling was used to include patients of different gender, age, wound duration and ty

126 In addition, the presence of a patient or colleague and use of a computer or telephone

127 e predictive value regarding tumor grade and patient outcomes.

128 ing as primary care providers with their own patient panel doubled.

129 e intent of bringing novel therapies to this patient population years before PFS results are mature.

130 about potential harms, benefits, costs, and patient preferences.

131 Patients presented with early-onset sensorineural deafne

132 e generated iPSC-derived cardiomyocytes from patients presenting in vivo with extremely low or high c

133 , the transcatheter aortic valve replacement patient presents a unique challenge as many patients are

134 All patients received anti-HCV treatment before or after inc

135 13 patients received treatment cycle 2; ten (77%) of the 13

136 s Honokiol as a promising therapy for cancer patients receiving Dox treatment.

137 ter observational study over 3 months of all patients receiving mechanical ventilation in 36 intensiv

138 who assess patients' smoking status, educate patients regarding ocular risks of smoking, and discuss

139 to explore the salivary microbiome of 61 FA patients regarding their oral health status and OSCC ris

140 Glaucoma patients reported varied degrees of concern regarding it

141 ody against VEGF, improves the proportion of patients responding to treatment in advanced gastric can

142 ) has become primary strategy for sequencing patient samples and study their genomics aberrations.

143 Most P. vivax studies must therefore rely on patient samples, which typically display a low proportio

144 care providers to perform HCV screening for patients seen in primary care clinic (1) born between 19

145 Although the proportion of patients shocked within 2 minutes of arrival increased d

146 ASPD patients showed decreased FA in multiple major white mat

147 nnequin (medium-fidelity anatomy), and (3) a patient simulated by a deceased donor (high-fidelity ana

148 ng ocular risks of smoking, and discuss with patients smoking cessation options.

149 proportion of eye care providers who assess patients' smoking status, educate patients regarding ocu

150 rticular importance to identify malnourished patients so that nutritional therapy can be instituted.

151 ults were consistent across the prespecified patient subgroups.

152 r dropped below 10 IU/mL, only one and three patients subsequently developed clinical and virological

153 Analyses controlled for patient-, surgeon-, and institution-level covariates.

154 The discovery cohort had 306 patients, the first validation cohort had 216, and the s

155 Patients then had pre-randomisation assessments with car

156 NIFICANCE STATEMENT By comparing brain tumor patients to healthy children, we establish that changes

157 linical assessment of volume status in these patients to help guide decongestive therapy.

158 may decrease hypoxemia without compromising patient tolerance.

159 Five-year OS was 86.8% and 78.8% for patients treated at GR and at MSKCC, respectively (P < 0

160 Despite an increased travel burden, patients treated at high-volume centers had improved per

161 etrospectively collected data on CHCs in all patients treated for childhood cancer at the St Jude Chi

162 and complications in acute coronary syndrome patients treated with extracorporeal circulatory support

163 mia and mantle cell lymphoma cell lines, and patients treated with idelalisib, but not ibrutinib, sho

164 of disease-modifying activity, even if some patients treated with interferon and ruxolitinib showed

165 pport ongoing efforts to centralize care for patients undergoing PD.

166 With adjustment, patients undergoing surgery by low-volume surgeons were

167 in the number of opioid pills prescribed to patients undergoing the same operation.

168 ompared with 176 patients undergoing ViV, 72 patients undergoing ViR had lower left ventricular eject

169 Compared with 176 patients undergoing ViV, 72 patients undergoing ViR had

170 tor use and 11 studies reported morbidity in patients using these medications at admission to ICU.

171 The patient was examined with ultrasound, sternal radiograph

172 The median age of the patients was 66 years, and 72% were men; 43% were enroll

173 Patients were 17 years old or younger and had Crohn's di

174 e examined differences in mortality when ICU patients were admitted under intensivists routinely work

175 Eligible patients were enrolled from 58 centres across 18 countri

176 Patients were followed up until death or were censored o

177 Hershey Medical Center, 95 patients were included in this systematic review.

178 Patients were randomized to the liberal (hemoglobin thre

179 Results Sixty-three patients were randomly assigned to docetaxel (n = 41) or

180 , 2014, 1647 self-harm presentations by 1153 patients were recorded.

181 Two male and three female patients were recruited in this study.

182 d that M1 maps of the amputated limb in TMSR patients were similar in terms of extent, strength, and

183 Ten relapsing-remitting MS patients were studied using the TSPO radioligand (11)C-(

184 renal failure and respiratory failure in one patient) were suspected to be related to everolimus trea

185 and disability pension levels can be used by patients when planning their work, by health care profes

186 ced rates of relapse in lestaurtinib-treated patients who achieved sustained greater than 85% FLT3 in

187 Patients who are chronically infected with hepatitis C v

188 In patients who are ineligible for revascularization proced

189 Patients who completed 6 months of treatment and remaine

190 In both trials, the proportion of patients who discontinued treatment because of adverse e

191 In patients who reached the symptom threshold after inulin

192 survival was not significantly different in patients who received a high FFP:RBC ratio compared with

193 Results As of October 13, 2016, 18 patients who received D + T 150/2 remained in the study

194 Patients who screened positive for HER1/2 and who did no

195 In a prospective study of 2106 patients who underwent EMR for large sessile or flat col

196 ngitudinal sample (cohort B) included 16 MDD patients who underwent MRI at baseline then 24 h followi

197 We collected HCC samples from 59 patients who underwent surgical resection from November

198 g all patients as well as the subset of LTFU patients who were alive, contacted in person by the trac

199 st Hospital, Houston, Texas, and included 10 patients who were scheduled for enucleation as primary t

200 rican, East or South Asian Canadians and for patients with "other" ethnic background, respectively.

201 Patients with 1 or more previous admissions to an urban

202 the clinical characteristics and survival of patients with ACOS identified in a real-life cohort of p

203 Most patients with acquired TTP respond to a combination of p

204 he presence of bursitis in more than half of patients with active disease.

205 Five eligible studies including 4360 patients with acute ICH were pooled in meta-analysis.

206 fect of MABp1 with a new primary endpoint in patients with advanced colorectal cancer.

207 he use of imatinib, in a large population of patients with advanced GIST.

208 Only 40% of patients with advanced ovarian cancer survive more than

209 y detection and improved visual outcomes for patients with age-related macular degeneration.

210 Of the 43249 patients with AML (mean [SD] age, 59.5 [16.6] years; 239

211 icance of CNA presence in disease relapse in patients with AML.

212 Results Between diabetic patients with and diabetic patients without DPN, mean ag

213 ned from 128 patients with exudative AMD, 46 patients with atrophic AMD and 111 healthy controls.

214 analysis, patients with irregular Z line and patients with BE of >/= 1 cm did not differ significantl

215 In patients with bicuspid aortic valve and dilated proximal

216 distal airway brushings were collected from patients with BOS (n = 10), stable lung transplant patie

217 evelopment of treatment solutions to benefit patients with breast cancer at high risk of recurrence.

218 Patients with cardiogenic shock or cardiac arrest on pre

219 -) were evaluated using flow cytometry in 32 patients with cGvHD treated by ECP for a minimum of 3 mo

220 w-LVAD database (n=354) was used to identify patients with chest computed tomographies performed in t

221 tion) trial, a clinical trial in which 2,604 patients with chronic angina and incomplete revasculariz

222 ifungal treatment is indicated in almost all patients with chronic cavitary pulmonary infections, chr

223 differences in individual cytokine levels in patients with chronic liver disease, but comprehensive c

224 It is a challenge to treat patients with cirrhosis using anticoagulants, because of

225 Among patients with cirrhosis, statin use decreased the risk o

226 Everyday visual search can be impaired in patients with common eye diseases like glaucoma and age-

227 te the associations and sensitizations among patients with concomitant AD and ACD.

228 ith ACOS identified in a real-life cohort of patients with COPD.

229 at MUC4 modulates corticosteroid efficacy of patients with CRSwNP.

230 calcium oxalate stone formation observed in patients with cystic fibrosis.

231 s with other clinical indications, including patients with diabetes mellitus and prediabetes and thos

232 The proportion of patients with documented well-controlled asthma in this

233 Individual data from 2092 patients with enteric fever randomized into 4 trials in

234 Plasma was obtained from 128 patients with exudative AMD, 46 patients with atrophic A

235 clusion, we demonstrate a relevant number of patients with FDG-PET false-negative MM and a strong ass

236 Patients with first-episode psychosis had lower regional

237 mber 30, 2016, and included both eyes of 100 patients with glaucoma or ocular hypertension.

238 ting budget impact between ECHO and non-ECHO patients with HCV were then compared.

239 Although beta-blockers increase survival in patients with heart failure (HF), the mechanisms behind

240 onic inflammatory diseases, such as COPD, in patients with hemoptysis, TAE of the BAA and of the path

241 re associated with functional improvement in patients with HF and reduced ejection fraction receiving

242 ection are not fully understood, and not all patients with HF respond favorably to them.

243 en, and ruxolitinib might extend survival of patients with higher-risk myelofibrosis.

244 lable data suggests that double mutations in patients with hypertrophic cardiomyopathy are not rare a

245 Based on this cutoff, 36.2% of patients with IBD in mucosal healing have increased inte

246 increased in inflamed intestinal tissues of patients with IBD.

247 The overall response rate for patients with IMT (treated at 100, 165, and 280 mg/m(2)/

248 ary analysis of the RIVER-PCI (Ranolazine in Patients with Incomplete Revascularization after Percuta

249 e SOFA and qSOFA classifications to identify patients with infection who are at elevated risk of poor

250 ng by allergists to offer BLAST for eligible patients with infectious diseases receiving nonpreferred

251 On multivariate analysis, patients with irregular Z line and patients with BE of >

252 Patients with isolated focal dystonia evaluated within 5

253 nt loss to follow-up) between the numbers of patients with laboratory-confirmed RR-TB and those repor

254 ted a retrospective study comprising the 606 patients with LQTS (LQT1 in 47%, LQT2 in 34%, and LQT3 i

255 Patients with lung or colorectal cancer often exhibit le

256 uring and progresses during interruptions in patients with macula-on RD.

257 Patients with major depressive disorder completed two rt

258 expression measured immunohistochemically in patients with metastatic breast cancer.

259 pply ichorCNA to 1439 blood samples from 520 patients with metastatic prostate or breast cancers.

260 17 patients with MS and 11 healthy controls (HCs) underwent

261 i-VEGF drug for the hundreds of thousands of patients with nAMD treated each year worldwide.

262 iopsies and blood samples were obtained from patients with newly diagnosed cardiomyopathy and clinica

263 A stratified random sample of 863 patients with newly diagnosed SCC of the oral cavity, or

264 troke prevention alternative to warfarin for patients with nonvalvular atrial fibrillation.

265 tis B virus (HBV) e antigen-positive viremic patients with normal liver function and the incorporatio

266 FFR into the decision-making process of ACS patients with obstructive coronary artery disease is ass

267 ecommendations, when data are available, for patients with other clinical indications, including pati

268 ing use of emergency departments among older patients with palliative needs has led to the developmen

269 Patients with pancreatic-insufficient cystic fibrosis (P

270 bjects with mild cognitive impairment (MCI), patients with Parkinson disease (PD), and young and olde

271 MMSE] </=25) using data from nine cohorts of patients with Parkinson's disease from North America and

272 ove the 90th percentile for the 5-mg dose in patients with preserved renal function.

273 events, we update prior recommendations for patients with prevalent coronary heart disease, and we o

274 We examined the proportion of patients with prevalent ESRD in each facility referred f

275 Up to 70% of patients with primary biliary cholangitis develop prurit

276 All patients with probable IA were repeatedly positive for b

277 ve cholangiocytes, in both murine models and patients with PSC.

278 Patients with psoriasis have an increased risk of myocar

279 In patients with radiographic evidence of metastases and mi

280 In approximately 50% of patients with RCDII, these Lin(-)IELs develop into a lym

281 ted carotid plaque (68)Ga-DOTATATE uptake in patients with recent carotid events, assessed inter- and

282 In patients with recurrent nasal polyposis receiving topica

283 Novel therapies are needed for patients with relapsed or refractory multiple myeloma (M

284 d comparison of two proteasome inhibitors in patients with relapsed or refractory multiple myeloma.

285 Patients with relapsing-remitting MS (RRMS) or clinicall

286 Patients with repetitive ventricular tachycardia/ventric

287 ing of antibiotics to improve the outcome of patients with sepsis.

288 Patients with severe extracranial injuries (AIS >/= 3),

289 MARS was used to support patients with severe liver trauma (SLT), in ALF patients

290 reduce need for parenteral support volume in patients with short bowel syndrome (SBS) with intestinal

291 itivity cardiac troponin I concentrations in patients with suspected acute coronary syndrome in which

292 Decreased SST-IR neurons in the amygdala of patients with SZ and BD, interpreted here as decreased S

293 major adverse cardiovascular outcomes among patients with T1DM.

294 Patients with testing ordered for C. difficile were enro

295 te, 58%), but its use should be reserved for patients with truly severe and refractory LyP.

296 trial (TACE 2) in 20 hospitals in the UK for patients with unresectable, liver-confined hepatocellula

297 Between diabetic patients with and diabetic patients without DPN, mean age (60 years [range, 38-79 y

298 HTS permitted identification of 19.9% of SR patients without MRD at any detectable level who had exc

299 e colitis, or IBD-unclassified with 24,543.0 patient-years of follow-up.

300 ministration of antibiotics to save lives of patients, yet the present benchtop molecular diagnosis i